Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 545 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT07065344Recruiting
A study of patients with DLBCL in the Middle East and Africa
This study looks at patients with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. It aims to understand how the disease is treated, what treatments are available, and how patients access newer therapies. You simply continue your regular care and the study team collects information.
Al MansurahAges Any age - NCT06788964RecruitingPhase 2
Bridge therapy with loncastuximab and rituximab before CAR-T for lymphoma
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
Salt Lake City, UtahAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06610344Recruiting
BHB supplement with CAR-T for lymphoma
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for post-transplant lymphoma that didn't respond to treatment
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT06552559RecruitingPhase 1/Phase 2
Selinexor plus ICE chemo for brain-involved B-cell lymphoma
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
SeoulAges 18 years+ - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT05933967RecruitingPhase 2
Orelabrutinib with R-CHOP for newly diagnosed lymphoma
This Phase 2 trial tests whether adding orelabrutinib to standard chemotherapy (R-CHOP) can improve treatment for people with newly diagnosed double-expressing diffuse large B-cell lymphoma. It’s intended for adults who are well enough to receive treatment and whose lymphoma is in the body (not in the brain/spinal fluid).
Nanchang, JiangxiAges 18–70 - NCT05800977RecruitingPhase 1/Phase 2
Study of a CAR-T cell treatment for lymphoma that returned
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
BeijingAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT04824950Recruiting
Blood DNA test in newly diagnosed mediastinal large B-cell lymphoma
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
LyonAges 18 years+ - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT04609046RecruitingPhase 1
Lenalidomide and nivolumab added to standard treatment for brain lymphoma
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
Los Angeles, CaliforniaAges 18 years+ - NCT04088422Recruiting
Blood test DNA study in mature B-cell lymphoma
This study looks at “cell-free DNA,” meaning tiny bits of DNA found in blood, in people with mature B-cell lymphoma. It may help doctors understand the disease better and how blood tests could be used to monitor it.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04661020RecruitingPhase 2
CD19 CAR-T for newly diagnosed high-risk large B-cell lymphoma
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
Hangzhou, ZhejiangAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT03571568RecruitingPhase 1/Phase 2
Study of BI-1206 plus rituximab, with or without acalabrutinib
This early-phase study tests BI-1206 combined with rituximab, and possibly adds acalabrutinib, in people with certain slow-growing B-cell lymphomas that have come back or did not respond to prior treatment. The goal is to see whether this treatment approach shrinks lymphoma safely and effectively.
Atlanta, GeorgiaAges 18 years+ - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT07165769RecruitingPhase 2
ZGR combo for newly diagnosed spleen lymphoma with large cells
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05487170RecruitingPhase 1/Phase 2
Early trial of RNK05047 for advanced cancers
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
Atlanta, GeorgiaAges 18 years+
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 545 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.